Earnings call transcript: IQE posts strong H1 2024 growth, debt-free balance sheet

IQE reported first-half revenue of GBP 64.6 million, up 43% year over year, with wireless revenue rising 40% to GBP 26.0 million and photonics increasing 45% to GBP 38.5 million; adjusted EBITDA reached GBP 6.0 million. The company ended the period with GBP 41.6 million of cash and no bank debt, marking a significant balance-sheet turnaround, and reiterated upgraded full-year guidance. Management expects at least 30% growth in both 2026 and 2027, supported by AI/data-center demand and long-term supply agreements, though Indium Phosphide substrate and rare-earth constraints remain execution risks.

Analysis

The investable change is not top-line growth but the shift toward contracted utilization: LTAs can turn a historically volatile compound-semiconductor foundry model into one that supports higher asset turns, lower working-capital volatility, and eventually a materially better EBITDA multiple. The catch is that reported profitability remains fragile; with gross margin still near breakeven, the current earnings profile is highly sensitive to yield, mix, and downtime during tool conversions. Cash generation should be judged after working capital and conversion capex, not adjusted EBITDA.

The market is likely pricing a clean AI-optics scarcity story after the sharp rerating, while the binding constraint is upstream Indium Phosphide availability and customer qualification timing. Substrate allocation can cap shipment growth even if end-demand remains strong; conversely, customer prepayments would be a significant positive because they transfer expansion funding and demand risk to customers. The most important 1-3 month catalyst is disclosure of additional LTAs with volumes, duration, take-or-pay terms, and prepayment mechanics—not another broad AI-demand statement.

A second-order read-through is modestly positive for Tower Semiconductor (TSEM), whose agreement may strengthen its optical/photonics ecosystem positioning, but not yet enough to move consolidated estimates. For Aixtron (AIXA), near-term tool conversion rather than greenfield reactor purchases is mildly negative for incremental order timing; sustained substrate tightness could defer a broader equipment cycle. Over 6-18 months, successful qualification of larger-diameter Indium Phosphide could shift value toward the limited suppliers able to deliver yield and volume, but that transition remains technically unproven.

Contrarian view: the stock's rerating may be ahead of the margin proof point. A debt-free balance sheet reduces insolvency risk, but it does not validate durable returns on capital; the company still needs to demonstrate that LTAs convert into gross-margin expansion rather than merely fuller utilization at low profitability.

Key Decisions for Investors

• Do not chase IQE momentum at current levels. Use a 1-3 month watch entry only after disclosure of contracted volumes/prepayments and evidence that gross margin improves sequentially; target a position sized as a high-volatility small-cap satellite, with thesis invalidated by a guidance cut or renewed net working-capital drain.
• If adding IQE, structure exposure through a staged long: initiate one-third after a confirmed LTA with enforceable capacity commitments, add only after the next results show positive operating cash flow after working capital. Risk/reward is attractive only if margin expansion, rather than revenue growth alone, is visible.
• Monitor AIXA for order-book commentary tied to InP capacity additions. Avoid using IQE's tool-conversion program as a positive AIXA read-through; consider AIXA only if customer commitments move from conversions to new-reactor orders over the next 6-12 months.
• Maintain TSEM as the cleaner liquid proxy for photonics/compound-semiconductor demand rather than extrapolating IQE's customer agreement into material TSEM earnings. Reassess if TSEM quantifies optical-photonics wafer volume or margin contribution in upcoming guidance.
• Set an alert for substrate shortages, export restrictions, or customer qualification delays: any evidence that InP allocation constrains shipments should prompt reducing IQE exposure, since the current valuation leaves little room for a volume shortfall.